Cancer in patients on dialysis for end-stage renal disease: an international collaborative study.
BACKGROUND
Previous studies have suggested that the frequency of cancer is higher in patients with end-stage renal disease (ESRD) than in the general population, but have not established whether this increase is confined to certain cancers or to certain categories of ESRD patients. The aim of this study was to examine the risk of cancer in a large cohort of patients treated by dialysis but not transplantation.


METHODS
We assembled a cohort of 831,804 patients who received dialysis during the period 1980-94 for ESRD in the USA, Europe, Australia, or New Zealand. We compared the observed frequency of cancer among these patients during 2,045,035 person-years of follow-up with the frequency of cancer in the respective background populations.


RESULTS
During average follow-up of 2.5 years, 25,044 (3%) of 831,804 patients developed cancer compared with an expected number of 21,185 (standardised incidence ratio 1.18 [95% CI 1.17-1.20]). We observed a higher risk of cancer in patients younger than 35 years (3.68 [3.39-3.99]), and the risk gradually decreased with increasing age. High risks were observed for cancer of the kidney (3.60 [3.45-3.76]), bladder (1.50 [1.42-1.57]), and thyroid and other endocrine organs (2.28 [2.03-2.54]). Excess cancers appeared in several organs for which viruses have been suspected as causative agents, whereas cancers of the lung, colorectum, prostate, breast, and stomach were not consistently increased.


CONCLUSIONS
The overall risk of cancer is increased in patients with ESRD, and the distribution of tumour types resembles the pattern seen after transplantation (although we have no data to make the comparison with skin cancer). The excess risk can largely be ascribed to effects of underlying renal or urinary-tract disease, or of loss of renal function, on the kidney and bladder, and to increased susceptibility to viral carcinogenesis. The relative risk, which is especially high in younger patients, gradually diminishes with age.
Maisonneuve
P
P
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. pmaison@ieo.it
Agodoa
L
L
Gellert
R
R
Stewart
J H
JH
Buccianti
G
G
Lowenfels
A B
AB
Wolfe
R A
RA
Jones
E
E
Disney
A P
AP
Briggs
D
D
McCredie
M
M
Boyle
P
P
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D001315:Australia / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D007223:Infant; D007676:Kidney Failure, Chronic / Q000145:classification / Q000150:complications / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000145:classification / Q000453:epidemiology / Q000209:etiology*; D009520:New Zealand / Q000453:epidemiology; D012042:Registries; D006435:Renal Dialysis / Q000009:adverse effects* / Q000706:statistics & numerical data; D012307:Risk Factors; D013997:Time Factors; D014481:United States / Q000453:epidemiology